- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00628732
A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors
A Pharmacokinetic and Phase II Study of Oral Cyclophosphamide and Oral Topotecan in Children With Recurrent and or Refractory Solid Tumors
The purposes of this study include:
- Determination of the change in clearance of topotecan and topotecan lactone between day 1 and day 14 for patients receiving treatment with p.o. topotecan and p.o. cyclophosphamide x 14 days.
- Determination of the correlation between the activity of CYP3A4, as measured by the 14C- Erythromycin Breath Test (ERMBT), and topotecan/topotecan lactone clearance for patients receiving treatment with p.o. topotecan and p.o. cyclophosphamide x 14 days.
- Determination of the response rate to oral cyclophosphamide and oral topotecan in recurrent and/or refractory pediatric solid tumors.
- Obtain additional safety data for the chemotherapy regimen, p.o. topotecan and p.o. cyclophosphamide x 14 days.
- Report the frequency of severe toxicities associated with the level of CYP3A4 activity, as measured by the ERMBT, for patients receiving treatment with p.o. topotecan and p.o. cyclophosphamide x 14 days.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Upon obtaining informed consent, patients will begin two courses of oral cyclophosphamide and topotecan x 14 days. During the first of two courses, patients will perform the 14C-Erythromycin Breath Test and have topotecan pharmacokinetics performed on day 1 and 14. The subjects will also have various medical tests and procedures performed that are part of regular cancer care which include: Medical history and physical examination to be done weekly, blood tests to be done weekly, heart and kidney function tests, various scans to be done after two courses of treatment, and a pregnancy test for females of childbearing age to be done prior to starting treatment.
Patients may continue to receive additional courses of oral cyclophosphamide and topotecan provided that they do not experience tumor progression or intolerable side effects.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75235
- Children's Medical Center Dallas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be less than 22 years of age inclusive
- Tumor histologies: medulloblastoma/PNET, neuroblastoma, sarcomas, and other pediatric solid tumors for which there is no known effective therapy.
- Patients must have measurable disease, documented by clinical, radiographic, or histologic criteria.
- Patients must have a performance status of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients <= 16 years of age.
- Patients must have a life expectancy of >= 8 weeks.
- Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
- Patients must not be taking the following medications: growth factors, steroids, and CYP3A4 inducers or inhibitors.
- Patients must have adequate bone marrow, renal, liver function, pulmonary, or central nervous system function.
- Must be able and willing to participate in all study procedures, including the ERMBT and pharmacokinetic studies.
- All patients and/or their parents or legal guardians must sign a written informed consent. (11) All institutional, FDA, and NCI requirements for human studies must be met.
Exclusion Criteria:
- Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- Patients with an uncontrolled infection.
- Allergy to erythromycin
- Patients who have previously received either cyclophosphamide or topotecan are eligible for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Radiographic imaging
Time Frame: Every 2 cycles
|
Every 2 cycles
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniel C Bowers, MD, UT Southwestern Medical Center of Dallas
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Cyclophosphamide
- Topotecan
Other Study ID Numbers
- 012005004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
Clinical Trials on Cyclophosphamide and Topotecan
-
Salarius Pharmaceuticals, LLCEnrolling by invitationEwing Sarcoma | Myxoid Liposarcoma | Desmoplastic Small Round Cell Tumor | Angiomatoid Fibrous Histiocytoma | Extraskeletal Myxoid Chondrosarcoma | Clear Cell Sarcoma | Myoepithelial Tumor | Sclerosing Epithelioid Fibrosarcoma | Low Grade Fibromyxoid SarcomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)Completed
-
Nicklaus Children's Hospital f/k/a Miami Children...TerminatedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Embryonal Tumor With Abundant Neuropil and True Rosettes | Metastatic Malignant Neoplasm to the LeptomeningesUnited States
-
Targeted Therapy Technologies, LLCActive, not recruiting
-
The Hospital for Sick ChildrenRecruiting
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; University of Colorado, Denver; Genentech, Inc.; Sidney... and other collaboratorsCompletedSarcoma | NeuroblastomaUnited States, Canada
-
University of California, San FranciscoHyundai Hope On WheelsCompletedMalignant Solid Tumor | Childhood Solid TumorUnited States
-
Actuate Therapeutics Inc.Active, not recruitingNeuroblastoma | Pediatric Cancer | Diffuse Intrinsic Pontine Glioma | Pediatric Brain Tumor | Refractory Cancer | Refractory Neoplasm | Refractory Tumor | Cancer Pediatric | Neuroblastoma Recurrent | Pediatric Lymphoma | Pediatric MeningiomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
Memorial Sloan Kettering Cancer CenterCompletedNeuroblastoma | Bone Marrow, Sympathetic Nervous SystemUnited States